Willkie represents PAI Partners on the contemplated acquisition of SGD Pharma, a world leader in the pharmaceutical glass packaging industry.
On June 16, Willkie client PAI Partners announced that it has made a binding offer for the acquisition of SGD Pharma, a leading global manufacturer of primary glass packaging for the pharmaceutical industry, to China Jianyin Investment Ltd. (JIC).
Headquartered in France, SGD Pharma employs 3,200 people worldwide, with a network of five industry-reference plants located in France, Germany, China, and India. It supplies Type I, II and III, molded and tubular, amber and flint glass packaging to a wide range of customers including international pharma laboratories, generics manufacturers, CDMOs, biotechs, and wholesalers.
Under JIC ownership, SGD Pharma has continuously invested in its industrial footprint and further accelerated its innovation efforts, strengthening its leadership and developing strong positions in attractive higher growth, as well as value, segments and geographies.
The contemplated transaction will be submitted to the relevant employee representative bodies of SGD Pharma and be subject to the finalization of the process required by the Ministry of Finance of China. The completion of the contemplated transaction would be subject to antitrust approvals.
The Willkie deal team was led by partners Christophe Garaud and Grégory de Saxcé and included associate Charlène Jouët on the corporate aspects as well as partner Faustine Viala and associates David Kupka and Maud Boukhris on the antitrust aspects of the transaction.